Otonomy Investor Relations Material

Latest events

Q2 2022


Q3 2022

10 Nov, 2022

Q2 2022

25 Jul, 2022
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Otonomy Inc

Access all reports
Otonomy, Inc. is a biopharmaceutical company, focuses on the development of therapeutics for neurotology in the United States. The company's lead product candidate is OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine that is being developed to treat tinnitus. In addition, the company has two Phase II clinical trials for OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor for the treatment of speech in noise hearing difficulties and repair cochlear synaptopathy remodeling caused by acute hearing loss.